Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) Institutional Ownership
CUSIP: 82835W108
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
186
Shares (Excl. Options)
88,975,649
Price
$11.65
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- SPRY on Nasdaq
- Shares outstanding
- 98,600,500
- Price per share
- $8.03
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 88,975,649
- Total reported value
- $1,036,368,369
- % of total 13F portfolios
- 0%
- Share change
- +5,012,599
- Value change
- +$65,098,405
- Number of holders
- 186
- Price from insider filings
- $8.03
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 82835W108.
- 186 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 186 to 11 between Q4 2025 and Q1 2026.
- Reported value moved from $1,036,368,369 to $1,215,634.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 186 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 82835W108?
CUSIP 82835W108 identifies SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue With The Right Next Step
- Latest 13F filings - identify new institutional portfolio moves.
- Latest Schedule 13D/13G reports - cross-check beneficial ownership events.
- All institutional ownership pages - compare nearby CUSIPs and holder concentration.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 82835W108:
Significant Owners of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | $111,050,917 | 10,940,977 | RA Capital Management, L.P. | 29 Sep 2025 | |||
| Flynn James E | 7.8% | -12% | $134,624,739 | -$18,102,531 | 7,610,217 | -12% | Deerfield Management Company, L.P. | 30 Jul 2025 |
| Rubric Capital Management LP | 6.3% | $70,556,000 | 6,200,000 | Rubric Capital Management LP | 31 Dec 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 6% | +12% | $48,748,087 | +$4,322,622 | 5,916,030 | +9.7% | Millennium Management LLC | 27 Mar 2026 |
| BlackRock, Inc. | 5.1% | $58,401,450 | 5,013,000 | BlackRock, Inc. | 31 Dec 2025 |
As of 31 Dec 2025, 186 institutional investors reported holding 88,975,649 shares of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY). This represents 90% of the company’s total 98,600,500 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | 10,860,977 | 0% | 1.3% | $126,530,382 |
| ORBIMED ADVISORS LLC | 8.4% | 8,288,510 | 0% | 2.1% | $96,561,142 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 7.6% | 7,503,812 | 0% | 1.1% | $87,419,410 |
| Rubric Capital Management LP | 6.3% | 6,200,000 | +38% | 0.86% | $72,230,000 |
| BlackRock, Inc. | 5.2% | 5,085,317 | +5.3% | 0% | $59,243,944 |
| SR One Capital Management, LP | 4.1% | 4,012,903 | 0% | 6.6% | $46,750,320 |
| Aberdeen Group plc | 3.6% | 3,556,049 | +15% | 0.06% | $41,427,971 |
| VANGUARD GROUP INC | 3.6% | 3,509,174 | +0.25% | 0% | $40,881,877 |
| STATE STREET CORP | 3.3% | 3,223,581 | +11% | 0% | $37,554,719 |
| MILLENNIUM MANAGEMENT LLC | 3.2% | 3,168,406 | 0.03% | $36,911,930 | |
| FRANKLIN RESOURCES INC | 2.6% | 2,543,097 | +6.1% | 0.01% | $29,627,082 |
| UBS Group AG | 2.2% | 2,210,866 | +235% | 0.01% | $25,756,589 |
| Tyro Capital Management LLC | 2% | 1,994,852 | 7.2% | $23,240,025 | |
| CITADEL ADVISORS LLC | 2% | 1,954,472 | +23% | 0.02% | $22,769,599 |
| Casdin Capital, LLC | 1.6% | 1,600,000 | 0% | 1.2% | $18,640,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,552,870 | +3.1% | 0% | $18,093,898 |
| Southpoint Capital Advisors LP | 1.5% | 1,500,000 | 0% | 0.41% | $17,475,000 |
| Janney Montgomery Scott LLC | 1.3% | 1,287,832 | +6.2% | 0.03% | $15,003,000 |
| BAMCO INC /NY/ | 1.3% | 1,268,532 | 0% | 0.04% | $14,778,398 |
| GOLDMAN SACHS GROUP INC | 0.82% | 812,036 | -39% | 0% | $9,460,219 |
| FIL Ltd | 0.82% | 810,073 | 0.01% | $9,437,350 | |
| LEVIN CAPITAL STRATEGIES, L.P. | 0.76% | 747,506 | -2.2% | 0.76% | $8,708,445 |
| Nextech Invest, Ltd. | 0.67% | 660,703 | 0% | 0.74% | $7,697,190 |
| BANK OF MONTREAL /CAN/ | 0.65% | 643,407 | 0% | $7,495,692 | |
| CenterBook Partners LP | 0.58% | 568,361 | +11% | 0.32% | $6,621,406 |
Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 148,014 | $1,215,634 | +$314,328 | $8.03 | 11 |
| 2025 Q4 | 88,975,649 | $1,036,368,369 | +$65,098,405 | $11.65 | 186 |
| 2025 Q3 | 83,632,743 | $840,434,931 | -$93,311,095 | $10.05 | 187 |
| 2025 Q2 | 84,521,210 | $1,475,027,148 | +$149,943,852 | $17.45 | 185 |
| 2025 Q1 | 76,226,291 | $958,937,759 | +$63,838,841 | $12.58 | 182 |
| 2024 Q4 | 71,304,827 | $752,320,202 | +$68,074,351 | $10.55 | 163 |
| 2024 Q3 | 63,765,651 | $925,913,322 | +$31,092,478 | $14.50 | 148 |
| 2024 Q2 | 62,590,275 | $533,041,807 | +$21,909,612 | $8.51 | 112 |
| 2024 Q1 | 59,892,345 | $612,088,771 | -$16,199,586 | $10.22 | 113 |
| 2023 Q4 | 65,423,068 | $358,517,051 | -$2,784,476 | $5.48 | 99 |
| 2023 Q3 | 66,524,840 | $251,464,826 | +$38,754,815 | $3.78 | 94 |
| 2023 Q2 | 55,071,412 | $368,976,724 | +$11,246,123 | $6.70 | 92 |
| 2023 Q1 | 53,405,274 | $347,669,060 | +$19,586,591 | $6.51 | 88 |
| 2022 Q4 | 50,164,476 | $427,856,540 | +$173,112,031 | $8.53 | 72 |
| 2022 Q3 | 30,422,972 | $160,377,408 | +$24,492,078 | $5.28 | 58 |
| 2022 Q2 | 26,061,019 | $110,514,000 | -$387,734 | $4.24 | 60 |
| 2022 Q1 | 26,983,988 | $94,707,000 | -$19,556,342 | $3.51 | 66 |
| 2021 Q4 | 30,103,833 | $200,460,000 | -$13,223,479 | $6.66 | 71 |
| 2021 Q3 | 28,894,700 | $288,363,500 | -$42,490,899 | $9.98 | 73 |
| 2021 Q2 | 27,989,545 | $864,603,729 | +$5,243,899 | $30.89 | 74 |
| 2021 Q1 | 27,691,694 | $1,205,836,321 | +$139,058,596 | $43.63 | 67 |
| 2020 Q4 | 24,444,347 | $1,127,544,026 | +$1,117,084,030 | $46.34 | 61 |